USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant

In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cmG35ga
via IFTTT

0 comments:

Post a Comment